Esaote and Schiller Americas announce strategic partnership to expand the sales channel in the cardiology imaging space

FISHERS, Ind., Nov. 13, 2025 /PRNewswire/ — Esaote, one of the world’s leading medical imaging companies, is proud to announce a new strategic partnership with Schiller Americas, a global leader in cardiopulmonary diagnostics. This collaboration strengthens both companies’ presence in the cardiovascular imaging market and marks a major step forward in bringing Esaote’s advanced ultrasound technology to more U.S. healthcare providers.

Through this partnership, Schiller Americas will offer Esaote’s innovative ultrasound systems — including the MyLab™ E80, MyLab™ A70, and MyLab™ Omega eXP — to its extensive cardiology network across the United States. The synergy between the two companies creates a powerful portfolio that delivers comprehensive diagnostic solutions designed to improve cardiac care and patient outcomes.

Esaote and Schiller have shared a strong global relationship for many years, and we’re thrilled to expand that collaboration into the U.S. market” said Thomas Will, Director of Ultrasound Sales at Esaote North America. “Our product lines complement each other perfectly, combining Schiller’s excellence in cardiopulmonary diagnostics with Esaote’s leadership in ultrasound imaging, to provide clinicians with a more complete diagnostic toolkit“.

This partnership represents a significant step forward in improving diagnostic accuracy in the U.S.cardiopulmonary field” said Francesco Iacona, CEO of SCHILLER Americas. “By combining Esaote’s ultrasound imaging expertise with our leadership in cardiopulmonary diagnostics, we are establishing a new standard for comprehensive diagnostic solutions for clinicians“.

The partnership underscores both organizations’ shared commitment to advancing cardiovascular imaging, providing physicians with high-quality, flexible solutions that enhance diagnostic precision and workflow efficiency.

About Esaote

Esaote S.p.A. is a leader in medical device manufacturing in the areas of Ultrasound, Dedicated MRI, and Healthcare IT. Esaote’s headquarters are in Genoa, Italy, with an international presence in over 100 countries. Esaote North America, Inc., as part of the international Esaote Group, continues to develop and distribute innovative medical imaging systems, with the support of one of the world’s leading medical imaging companies.

About Schiller

SCHILLER Group, based in Baar, Switzerland, is a world-leading manufacturer and supplier of devices for cardiopulmonary diagnostics and patient monitoring, as well as software solutions for the medical industry.

As part of the SCHILLER Group, SCHILLER Americas, Inc. is committed to delivering the latest cardiopulmonary technology to the United States, Canada, and Latin America.

Photo – https://healthtechnologynet.com/wp-content/uploads/2025/11/MyLab_E80_Esaote_Ultrasound_system.jpg
Logo – https://healthtechnologynet.com/wp-content/uploads/2025/11/Esaote_North_America_Logo.jpg
Logo – https://healthtechnologynet.com/wp-content/uploads/2025/11/SCHILLER_Logo.jpg

View original content to download multimedia:https://www.prnewswire.com/news-releases/esaote-and-schiller-americas-announce-strategic-partnership-to-expand-the-sales-channel-in-the-cardiology-imaging-space-302612036.html

SOURCE Esaote North America

Staff

Recent Posts

Arspura Showcases a New Standard for Healthy Kitchen Living at CES 2026

LOS ANGELES, Dec. 25, 2025 /PRNewswire/ -- From January 6–9, 2026, visitors can experience Arspura's…

2 hours ago

XTL Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency

RAMAT GAN, ISRAEL, Dec. 24, 2025 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) (TASE:XTLB.TA) (the…

11 hours ago

Relapse Risk Increases During the Holidays; Desert Hope Treatment Center Urges Early Support

LAS VEGAS, Dec. 24, 2025 (GLOBE NEWSWIRE) -- This holiday season, addiction experts at Desert Hope…

11 hours ago

Profound Medical Corp. Announces Upsize of Private Placement

TORONTO, Dec. 24, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the…

11 hours ago

ImmuCell Announces Strategic Focus on First Defense® After Receiving an FDA Incomplete Letter for Re-Tain®

PORTLAND, Maine, Dec. 24, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell”), an animal…

11 hours ago